Expert Profile
Joshua Grill
Director of the Institute for Memory Impairments and Nerological Disorders at UCI
Joshua Grill directs a major Alzheimer's disease research institute helps lead the national strategy for AD clinical trial recruitment.
Areas of Expertise
- Neuroscience
- Clinical Trials
- Alzheimer’s Disease
- Neurodegenerative disorders
- Recruitment and Retention
Biography
Dr. Grill has been the recipient of the National Alzheimer’s Coordinating Center Junior Investigator Award, the Alzheimer’s Association Turken Research Prize, the Community Spirit Award from OPICA Adult Day Services, and the P. Gene and Elaine Smith Term Chair in Alzheimer’s Disease Research. He has been funded by the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, the Alzheimer’s Association, the Hartford Foundation, the BrightFocus Foundation, the American Federation for Aging Research, and the University of California. He is the co-leader of the Recruitment Unit and the Internal Ethics Committee for the NIH-funded Alzheimer’s Clinical Trial Consortium. He is a member of the Scientific Advisory Board for Maria Shriver’s Women’s Alzheimer’s Movement and for Lauren Rogen Miller and Seth Rogan's HfC. In 2017, he co-chaired a workgroup as part of the NIH’s Inclusion Across the Lifespan workshop, a congressional mandate in the 21st Century Cures Act (P.L. 114-255). He was part of a working group sponsored by the National Institute on Aging and the Alzheimer’s Association charged with creating a national strategy for recruitment to Alzheimer’s disease clinical research.
Media
Media Appearances
New Alzheimer’s drugs bring hope. But not equally for all patients.
The Washington Post, 1/29/2024
Sound waves get Alzheimer’s drug past brain barrier, small study shows
The Washington Post, 1/8/2024
Meet Orange County’s 125 most influential people for 2023
The Orange County Register, 12/22/2023
Researchers testing out drug for Alzheimer's prevention
Scripps News, 11/13/2023
Alzheimer’s drug trials plagued by lack of racial diversity
Nature, 8/2/2023
Insight: Promising new Alzheimer's drugs may benefit whites more than Blacks
Reuters, 7/31/2023
Potential Benefit of Nicotinamide Observed in Proof-Of-Concept Trial of Alzheimer Disease
Neurology Live, 7/18/2023
OC 50 2023 – 50 Shaping the Future of Healthcare in OC
Orange County Business Journal, 5/30/2023
Dementia doubles in Orange County in less than a decade
The Orange County Register, 5/1/2023
Watch out, Alzheimer’s! Big new grant at UCI, new drug trial at Hoag coming for you
The Orange County Register, 9/23/2022
Doctors and researchers encourage people to be mindful of their brain health
WTVY, 9/22/2022
Articles
Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer’s trials
Alzheimer's Research & Therapy, 1/1/1970
Participant and study partner prediction and identification of cognitive impairment in preclinical Alzheimer’s disease: study partner vs. participant accuracy
Alzheimer's Research & Therapy volume, 1/1/1970
Response to “Avoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosure”
Alzheimer's Research & Therapy, 1/1/1970
Retention of Alzheimer Disease Research Participants
Alzheimer Disease & Associated Disorder, 1/1/1970
Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials?
Alzheimer Disease & Associated Disorders, 1/1/1970
Education
Wake Forest University School of Medicine
PhD, Neuroscience, 2004
Accomplishments
- Community Spirit Award
- Junior Investigator Award
- Turken Research Prize
- P. Gene and Elaine Smith Term Chair